Abbott Laboratories (NY:ABT)

97.50 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

58 59 Next >

Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock ↗

October 14, 2024

Via Benzinga

Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗

October 14, 2024

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Via Talk Markets

Columbus Day: Is Stock Market Open Today? ↗

October 14, 2024

Investors should brace for a busy week with earnings reports from major companies.

Via Benzinga

Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth ↗

October 08, 2024

Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion.

Via Benzinga

A Look Into Abbott Laboratories Inc's Price Over Earnings ↗

October 08, 2024

Via Benzinga

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 08, 2024

Via Benzinga

How Is The Market Feeling About Abbott Laboratories? ↗

October 07, 2024

Via Benzinga

Navigating 6 Analyst Ratings For Abbott Laboratories ↗

September 26, 2024

Via Benzinga

Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors. ↗

September 11, 2024

Is ABBOTT LABORATORIES (NYSE:ABT) a Strong Candidate for Quality Investing?

Via Chartmill

3 Magnificent Dividend Stocks to Buy in October ↗

October 06, 2024

These dividend stocks are great picks as the fall season gets underway.

Via The Motley Fool

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades ↗

October 05, 2024

Investors can find market-trouncing blue chip stocks in the healthcare industry.

Via The Motley Fool

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗

October 03, 2024

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Via Investor's Business Daily

Topics Stocks

Down More Than 50%, Is DexCom Stock a Bargain Now? ↗

October 02, 2024

Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market.

Via The Motley Fool

2 Excellent Dividend Stocks to Buy With Less Than $200 ↗

September 28, 2024

Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.

Via The Motley Fool

Looking Into Abbott Laboratories's Recent Short Interest ↗

August 29, 2024

Via Benzinga

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗

September 25, 2024

These dividend players could lift your portfolio no matter what the market is doing.

Via The Motley Fool

Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst ↗

September 19, 2024

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation.

Via Benzinga

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 19, 2024

Via Benzinga

20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates ↗

September 18, 2024

Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market is divided on the magnitude of the cut, which could trigger significant...

Via Benzinga

Topics Economy Stocks

Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns

September 17, 2024

These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025.

Via MarketBeat

Topics Economy

Can AbbVie Regain Its Status As a Top Dividend Growth Stock? ↗

September 16, 2024

The dividend growth powerhouse is turning the corner.

Via The Motley Fool

Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy? ↗

September 16, 2024

The company continues to flex its innovative muscles.

Via The Motley Fool

3 Stocks to Buy and Hold Forever ↗

September 14, 2024

These stocks are built for the long run.

Via The Motley Fool

3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold ↗

September 13, 2024

These stocks have increased their payouts for decades.

Via The Motley Fool

2 Stocks That Are Passive Income Machines to Buy and Hold Forever ↗

September 11, 2024

You can take these dividends straight to the bank.

Via The Motley Fool

Medtronic Stock: Growth On Rise of the Cardiovascular Machines

September 09, 2024

Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases

Via MarketBeat

Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System ↗

September 05, 2024

Abbott recalls some FreeStyle Libre 3 sensors due to incorrect glucose readings, risking severe health issues.

Via Benzinga

Topics Product Recall

Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device ↗

September 05, 2024

The companies are now duking it out for a new population of CGM users.

Via Investor's Business Daily

3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever ↗

August 30, 2024

These three have secure core businesses, plus multiple paths to grow.

Via The Motley Fool

Patchy But Still Bullish ↗

September 02, 2024

Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations.

Via Talk Markets

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.